Company Overview

Cardiff Oncology, Inc. (CRDF) is a clinical-stage biotechnology company focused on the development of novel oncology therapeutics that target the tumor microenvironment. The company operates within the biopharmaceutical and oncology drug development industry, with an emphasis on improving treatment outcomes for patients with solid tumors through combination therapies. Its core strategy centers on enhancing the efficacy of existing cancer treatments rather than developing standalone cytotoxic agents.

The company’s primary asset is onvansertib, an orally administered, highly selective Polo-like kinase 1 (PLK1) inhibitor. Onvansertib is being evaluated across multiple cancer indications, primarily in combination with standard-of-care therapies, with a current focus on metastatic colorectal cancer and other solid tumors. Cardiff Oncology was originally founded as Trovagene, Inc. and transitioned its strategic focus following the acquisition of onvansertib, subsequently rebranding as Cardiff Oncology to reflect its oncology-centered pipeline and clinical mission.

Business Operations

Cardiff Oncology operates as a single-segment clinical-stage biotechnology company, generating no commercial product revenue and relying primarily on equity financing to fund operations. Its business activities are centered on clinical development, regulatory strategy, and translational research related to onvansertib, which represents the company’s sole clinical development program. Clinical trials are conducted in collaboration with academic cancer centers and clinical research organizations, primarily in the United States.

The company does not currently maintain manufacturing or commercialization infrastructure, instead outsourcing clinical manufacturing and trial execution. Cardiff Oncology holds global development and commercialization rights to onvansertib and focuses on biomarker-driven patient selection to potentially differentiate its therapy within competitive oncology markets. As of publicly available disclosures, the company does not report material joint ventures or revenue-generating subsidiaries.

Strategic Position & Investments

Cardiff Oncology’s strategic direction is focused on advancing onvansertib through mid-stage clinical trials and expanding its potential use across multiple tumor types through combination regimens. Growth initiatives include ongoing Phase 2 clinical trials in metastatic colorectal cancer, particularly in genetically defined patient populations, as well as exploratory studies in other solid tumors. The company emphasizes precision medicine and biomarker-driven development as a means of increasing clinical success probability.

The company’s most significant historical investment was the acquisition of onvansertib, which repositioned its pipeline and long-term strategy. Cardiff Oncology does not maintain a diversified portfolio of subsidiaries or external investments and has not announced material acquisitions beyond its core asset. Its strategic positioning is that of a focused, single-asset oncology developer seeking value creation through clinical validation and potential partnering or licensing opportunities.

Geographic Footprint

Cardiff Oncology is headquartered in the United States, with its principal executive offices located in California. The company’s operational footprint is primarily domestic, with clinical trial activities concentrated in North America, particularly at U.S.-based oncology centers. International operations are limited and largely indirect, occurring through global suppliers and service providers supporting clinical development.

While Cardiff Oncology does not maintain significant physical operations outside the United States, its intellectual property strategy and future commercialization plans are intended to support potential global market access. Any international influence at present is primarily related to regulatory planning and long-term market considerations rather than active overseas operations.

Leadership & Governance

Cardiff Oncology is led by an executive team with experience in oncology drug development, clinical research, and life sciences finance. The leadership emphasizes disciplined clinical execution, biomarker-driven development, and strategic capital management to advance its pipeline efficiently.

Key executives include:

• Mark Erlander – Chief Executive Officer
• Roger Sidhu – Chief Financial Officer
• James V. Cassella – Chief Development Officer
• Peter Ordentlich – Chief Scientific Officer

The company is governed by a board of directors with backgrounds in biotechnology, oncology, and public company oversight. Leadership has articulated a strategic vision centered on transforming onvansertib into a differentiated oncology therapy through rigorous clinical validation and targeted patient selection.